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IDENTIFICATION OF NATURAL FOOD EXTRACTS HAVING A POTENTIAL 
TO IMPROVE METABOLIC PHENOTYPE IN HUMANS 
 
DAMIEN JERMAINE SWEARING 
 
ABSTRACT 
According to the latest facts and figures from the Centers for Disease Control, the 
prevalence of obesity and Type-2 Diabetes Mellitus (T2DM) across all demographics is 
escalating worldwide. Among the range of drugs used to treat diabetes there is an interest 
in treatment options that are derived from more traditional methods, outside of the 
customarily synthetic and pharmaceutically sourced treatment options. Amid treatment 
alternatives that are more traditional in origin are a category of compounds called natural 
products. The natural products of interest are either plant based extracts or specific 
organic compounds extracted from the natural product. Over the last decade, plant based 
natural products have been increasingly shown to provide an alternative and 
supplementary course of treatment for diabetic patients suffering from systemic 
inflammation and insulin resistance in model systems of metabolic disease. However, 
information for many natural products is limited to small studies with mixed outcomes 
and information on human models systems remains limited in scope. In this thesis the 
most potent therapeutic natural products were evaluated by conducting a thorough 
literature review and subsequently studying the most promising candidates by 
characterizing their metabolic effects on human adipocytes. In order to identify the most 
	  	   vi	  
potent plant based natural products we will use cultured human adipocytes as a model 
system. Free-fatty acids (FFA) and cytokines including Tumor Necrosis Factor-alpha 
(TNF-α), have been demonstrated to impair fat metabolism and reduce insulin signaling. 
Therefore, we will study the protective effect of prominent and potentially beneficial 
natural compounds, based on comprehensive literature reviews, to assess their effect on 
FFA metabolism using glycerol release as a measure of lipolysis, cytokine induced 
lipolysis as a measure of natural product protection against inflammation, and impaired 
AKT-phosphorylation as a measure of insulin signaling function. Observations gathered 
concluded that the application of bitter melon, fenugreek, and ginseng plant extracts 
reduced lipolysis in a dose dependent manner, limited the effects of TNF-α induced 
lipolysis, and fenugreek and ginseng displayed pro-apoptotic cellular programs.  
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INTRODUCTION 
 
According to the latest facts and figures from the World Health Organization 
(WHO), the prevalence of Diabetes Mellitus (DM) across all demographics is escalating 
worldwide to historic levels and revealing troubling statistics 1. The WHO estimated that 
9% of adults over the age of 18 or 382 million people had diabetes and with 1.5 million 
individuals dying annually directly from DM complications, that by 2030 it will rise to be 
the 7th leading cause of death 2. Even from a cursory glance at the state of diabetes, the 
outlook does not appear to be positive and the societal burden of treating those with DM 
is becoming more cumbersome.  
Diabetes is a complex metabolic disorder that affects the body’s ability to control 
its regulation of the hormone insulin. Insulin is a pancreatic hormone that adjusts the 
body’s ability to regulate systemic glucose production and utilization by facilitating 
glucose uptake into cells. If insulin levels cannot be adequately controlled, systemic 
glucose levels remain elevated in a condition referred to as hypoglycemia and energetic 
cellular processes are unable to be controlled. Diabetes results in a range of debilitating 
complications such as heart disease, stroke, kidney disease, blindness, and amputation 1. 
Diabetes can take three main forms known at type 1, type 2 and gestational diabetes 3.  
 
Treating DM and Obesity 
 Due to the increasing numbers of individuals with T2DM, treatment is not just a 
large public health concern, but also a major business. Complications resulting from 
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diabetes increase the number of those seeking relief from various symptoms and expand 
the range of services that are desired from diabetic patients. In 2013, diabetes accounted 
for 10.8% of all healthcare treatment expenditures around the world 4. Modern diabetes 
treatment relies on both lifestyle changes and drug intervention. Lifestyle changes in 
patients with DM are focused on reducing caloric intake and improving physical 
activity5. Drugs used to treat the various complications from diabetes target fat 
distribution, dyslipidemia, hyperglycemia, hypertension or inflammation. Insulin 
treatment was the first major interventional treatment used. The market has expanded to 
include sulfonylureas, meglitinides, and dipeptidylpeptidases which increase insulin 
secretion, biguanides such as metformin that improve insulin sensitivity, and alpha-
glucosidase inhibitors that impede starch digestion. Thiazolidinediones (TZDs) are a 
major drug class used to treat diabetes. TZDs act as agonists for the nuclear receptor 
peroxisome proliferator-activated receptor gamma (PPAR-γ) which act as adipocyte 
sensors for lipid metabolism, recruit GLUT-4 receptors to cellular membranes and 
promote adipocyte differentiation 6. Despite advances made in drug development, the 
attempt at making drugs that selectively serve as ligands for PPAR-γ, including notable 
attempts like troglitazone are remembered as failures because of their often fatal 
hepatotoxicity 7. Rosiglitazone and pioglitazone, both relatively commercially successful 
PPAR-γ agonists are also coming under fire after reports suggest that both drugs can 
cause heart failure, stroke, and liver failure 8. A cursory investigation into the usage of 
natural products and their development into mature drugs and medicines reveals that 
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natural products often serve as significant sources of inspiration and guidance for 
therapeutic treatments. 
There are drugs on the market that address obesity such as olistat which limits 
intestinal fat absorption by interrupting the action of pancreatic lipase and sibutramine  
which acts as an appetite suppressant 9. However, both orlistat and sibutramine are 
expensive and induce a range of undesirable side-effects and complications that are 
encouraging pharmaceutical researchers and developers to pursue more safe and less 
reactive alternatives including crude extracts or isolated compounds from plants. 
Exploring the range of possibilities used to treat obesity related conditions can classify 
the efficacy of certain natural products based on the ability to decrease lipid absorption, 
decrease energy intake, increase energy expenditure, reduce adipocyte differentiation and 
proliferation, and reduce the amount of lipogenesis and increasing the amount of lipolysis 
9. Orlistat is derived from Streptomyces toxytricini, pancreatic lipase inhibitor but current 
alternatives that inhibit pancreatic lipase activity include saponins, polyphenols, and 
flavonoids from the Panax japonicas (Ginseng), Platycodi radix (Bellflower), Salacia 
reticulata (Salacia), and Nelumbo nucifera (Lotus) plants 9. Similarly the appetite 
suppressant activity of sibutramine acts by increasing sensations of satiety but natural 
product alternatives include Garcinia cambosia (Brindleberry), Citrus aurantium (Bitter 
orange), Robinia pseudoaccacia (Black Locust), and Phaseolus vulgaris (Common Bean) 
have all been investigated for various mechanisms of appetite suppression with some like 
Korean Red Ginseng reducing neuropeptide Y levels or Hoodia gordonii (Hoodia) 
reducing ATP levels in hypothalamic neurons controlling food intake in rat brains 9. The 
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thermogenic effect known to enhance energy dissipation within mitochondria from 
proton uncoupling in brown adipose tissue has been investigated as a drug target by 
studies on extracts from Solanum tuberosum (Potato) and fucoxanthin derived from 
chloroplasts. Attempts at limiting adipocyte differentiation using extracts from Cordyceps 
militaris, a fungal species, and targeting expression of PPAR-γ to improve dyslipidemia 
and improve insulin sensitivity using the shrub Salacia oblonga root have been 
investigated as well9. Certain cocktails in a range of component ratios have tried to 
combine the suspected benefits of these natural products and leverage any potential 
synergistic effects 10,11.  
An interesting development in potential therapeutics for DM and obesity suggests 
a link between adipose tissue and targeted apoptosis12. Apoptosis is a regulated process 
that is unique from necrosis that overseas systemic cellular homeostasis by inducing 
cellular suicide mechanisms13. Obesity is denoted by the proliferation and hypertrophy of 
adipocytes and inhibiting either characteristic of obesity presents a possible target for 
obesity treatment. Experiments have determined that the inactivation of pro-apoptotic 
BH3 interacting domain agonist (BID) molecule and the gene deletion of death receptor 
Fas (CD95) prevented inflammation from immune cell proliferation, limited the 
development of insulin resistance, and reduced hepatic steatosis in rodents 14. In humans, 
Fas expression was shown to also have a strong correlation in adipocyte apoptosis, 
obesity, insulin sensitivity, T2DM, and fat distribution compared to lean individuals 15. 
Additionally, TNF-related apoptosis-inducing ligand (TRAIL) up regulation and B-cell 
lymphoma 2 (bcl-2) gene inhibition may be responsible for the resistance of mature 
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adipocytes are less sensitive to apoptosis compared to pre-adipocytes 14. Thus, targeting 
and inducing tissue specific adipocyte apoptosis may serve as a viable treatment 
paradigm in treating DM and obesity. As a result of the relationship between apoptosis 
and metabolic disease symptoms, the promise of target apoptotic therapy is also being 
investigated in compounds such as phenols in curcumin or green tea, flavonoids from 
soybean products and, and less prevalent natural product components12.  There is a clear 
trend towards the investigation of natural products and adipocyte apoptosis. Preliminary 
data in model systems have demonstrated associations between several natural products 
and pro-apoptotic mechanisms in adipocytes.  
 
Natural Products and Diabetes and Obesity 
Among the range of treatments used to treat diabetes and obesity there is an 
interest in treatment options that are derived from more traditional methods, outside of 
the customarily synthetic and pharmaceutically sourced treatment options. Popular 
alternative medicine paradigms for treatment still persist including forms of Ayurveda, a 
Sanskrit term dating to its use in the Vedas in 1500BC used to encompass a view of 
practice of integrating mental, physical, spiritual, and social aspects of life and keeping 
them in a harmonious balance because to fail to do so may result in disease 16. Ayurveda 
incorporates principles of the use of many raw materials including drugs, metals, and 
plant based natural products to accomplish the sort of stability highlighted in this ancient 
practice. While the specific mechanisms are difficult to outline, many Ayurvedic writings 
of the treatment of diabetes and obesity include the use of bitter gourd, fenugreek, aloe 
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vera, cinnamon, and turmeric to act as possible inhibitors of glucose absorption or 
delayers of gastric emptying 17,18. Similarly, traditional Chinese medicines have also 
employed the use of a variety of herbs and spices, many of which are only found in that 
region of the world, to treat a range of symptoms and conditions relating to diabetes and 
obesity (Figure 1)19. Many of these concoctions have been in use for hundreds of years 
and while they may lack some of the precise conjecture of modern medicine, their 
anecdotal yet relatively consistent reputation remain strong. Of note is that regardless of 
the origin, the claims suggested by administrators of these common natural products 
claim to suggest similar outcomes.  
 
Figure 1: From: Hypoglycemic herbs and their action mechanisms20 Adapted from Hui 
et al, Hypoglycemic herbs and their action mechanisms (Chinese Medicine, 2009.) 
 
As a function of the need for cheaper and more widely available alternative or 
supplementary treatments in conditions like diabetes and obesity, the investigation in raw 
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natural products or their isolated components is of significant interest. The National 
Center for Complementary and Integrative Health (NICCH), a department within the 
National Institutes of Health (NIH), is tasked with investigating alternative medicine 
claims, including the efficacy of natural products across a spectrum of diseases and 
disorders as sources of drugs or therapeutic supplements. According to the NCCIH in an 
extensive study done in 2007, the uses of complementary and alternative medicine 
(CAM) by way of natural products accounted for nearly 20% of all methods used for 
treatment, of which plants and plant derivatives accounted for most of the natural 
products being used 21. Additionally, interest in natural product use increases in age and 
is not evenly distributed between demographics in the United States with Native 
Americans, Whites and Asians leading the interest in alternative medicines 21. In fact, the 
potential usefulness of natural products is seen in a Canadian study that remarked that 
78% of diabetic patients were also taking a supplementary natural product22. Research 
into natural products initially waned in the late 1990s. The cause for the initial decline 
was as a result of focus on the financial incentive and return on investment of blockbuster 
drugs, the rise of combinatorial chemistry that narrowed chemical diversity based on 
enhanced screening, advancements in identifying molecular targets that shorted drug 
discovery timelines, and a reduction in infectious disease therapy23.  An already limited 
access to resources to develop these drugs meant that screening functionally infinite 
sources of natural compounds took a back seat to developing items that reduced 
mechanical guesswork. According to Koehn and Carter, natural products are a, 
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“population of privileged structures selected by evolutionary pressures to interact with a 
wide variety of proteins and other biological targets for specific purposes23.”  
 
Thesis Goal  
Our goal was to investigate the potency of several raw natural products as a 
function of supporting evidence and efficacy from the academic literature and how these 
products interact with human adipocytes. The most potent therapeutic natural products 
were identified by conducting a thorough literature review of the compounds in question 
and their related methodology, model system, and outcomes. FFAs and cytokines such as 
TNF-α have also been demonstrated to impair fat metabolism and reduce insulin 
signaling and in conjunction with the raw application of these natural products to human 
adipocytes we could determine their response on adipocyte function. Cultured primary 
human adipocytes benefits from specific morphological advantages including sensitivity 
to insulin resistance and metabolic conditions resembling systemic obesity, and as such, 
will serve as an ample model system24–26. The main aim is to study the possibility of a 
protective effect with respect to the use of natural compounds on human adipocyte 
function. Aspects of adipocyte function will be considered using glycerol release as a 
measure of lipolysis, cytokine induced lipolysis as a measure of natural product 
protection against inflammation, impaired AKT-phosphorylation as a measure of insulin 
signaling function, and p53 mRNA expression as a measurement of adipocyte apoptosis.  
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METHODS 
Natural Product Selection  
A comprehensive data search back 10 years was completed using PubMed searches for 
experiments, clinical trials, and reviews using keywords containing “natural products, 
plant natural product, natural product diabetes, and natural product obesity.” The 
following paradigm shown in Figure 2 was used to select natural products that were 
supported by sound research, tested in a range of animal models, and availability. 
Candidate natural products were then used as a gauge of adipocyte function with respect 
to adipocyte morphology, apoptotic signaling measured with RT-PCR, insulin signaling, 
TNF-α as a measure of cytokine induced insulin resistance, and the rate of lipolysis.  
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Figure 2: Working methodology  
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Natural Product Isolation 
Four natural products were tested: Bitter melon (Momordica charantia), liquid ginseng 
(Panax ginseng) extract, fenugreek (Trigonella foenum-graecum) seeds, and almonds 
(Prunus dulcis). Bitter melon was obtained from Ming’s Supermarket in Boston, MA, 
Ginseng extract under the name Red Panax Ginseng Extractum was obtained from GNC 
in Boston, MA, Fenugreek seeds were obtained from Ming’s Supermarket in Boston, 
MA, and Almonds were obtained from Walgreens in Boston, MA. 10 g of fenugreek 
seeds and 1.89 g of almonds were left to soak overnight in 20 mL of deionized water to 
soften the natural products and aid their manipulation. A 9.5 g segment of bitter melon, in 
addition to the fenugreek seeds and almonds were ground individually in a mortar and 
pestle, syringe filtered using 0.22 µm filters, and centrifuged at 13,000 rpm for 5 minutes. 
The supernatants of each natural product were isolated and placed in separate containers 
as raw stock for experimentation. Ginseng extract was used in its liquid commercial 
form. All natural product isolations were refrigerated at 4 ℃.  
Cell Culture 
Human preadipocytes were procured from the Boston Nutrition Obesity Research 
Center adipocyte core. Cells were seeded at a density of 5,000 cells/ml/well in a 12-well 
plate, in growth medium, which was made using 13.5 g of α-MEM powder (Life 
Technologies) with 10% FBS (Life Technologies), 100 units/ml of penicillin and 
streptomycin (Life Technologies), and 25 mM sodium bicarbonate (Fisher Scientific) 
reconstituted in double-distilled water (ddH2O) to 1 liter, pH 7.2–7.3. This growth 
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medium was changed every 2 days, until cells reached 90% confluence. To allow the 
cells to differentiate, the GM was then replaced by complete differentiation medium, 
which consisted of: 13.5 g of DMEM powder/F12 (Life Technologies), 100 units/ml of 
penicillin and streptomycin (Life Technologies), 15 mM Hepes (Sigma), 25 mM sodium 
bicarbonate (Fisher Scientific), 33 µM biotin (Sigma), 17 µM pantothenate (Sigma), 0.5 
mM isobutylmethylxanthine (Sigma), 10 mg/liter transferrin (Sigma), 1 µM 
Rosiglitazone (BIOMOL), 100 nM dexamethasone (Sigma), 100 nM human insulin 
(recombinant), 2 nM triiodo-L-thyronine (Sigma), reconstituted in ddH2O to 1 liter, pH 
7.4. The day cells were first given complete differentiation medium is designated as day 
0. The medium was changed every 2 days until the preadipocytes were fully 
differentiated into mature human white adipocytes that were filled with lipid droplets. 
Following differentiation, the cells were maintained in maintenance medium until fully 
differentiated with the medium being changed every 2 days. Maintenance medium was 
made of the similar constituents as complete differentiation medium, except without 
Rosiglitazone, isobutylmethylxanthine, triiodo-L-thyronine, and transferrin. Additionally, 
the concentrations of human insulin and dexamethasone used were 10 nM each. 
Experiments that were tested on human pre-adipocyte fibroblasts used cells were in their 
pre-differentiated stages. 
Experimental cell treatments with natural products ranged from concentration 
ratios of 0.1µl/ml to 50 µl/ml of natural product to either maintenance media or 
differentiation media. Each natural product concentration was made using the raw stock 
isolations that were first sonicated for 30 seconds at 2 second intervals on level 2 of the 
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Sonic Dismemberator 550 (Fisher Scientific). Treatment of each natural product involved 
the removal of 1 ml of the existing media in each cellular well and the addition of 1 ml of 
the corresponding natural product and cellular media concentration. Each application of 
each natural product lasted 24 hours upon which cells were harvested and analyzed. 
Applications of TNF-α (Sigma Aldrich) were done such that 10 ng per milliliter of 
cellular maintenance or differentiation media.27	  
Lipolysis Assay 
Lipolysis Assay—For analysis of total cellular glycerol and fatty acid release, cells 
were incubated in Krebs-Ringer buffer (24.6 mM NaHCO3 , 1.11 mM KH2 PO4 , 130 
mM NaCl, 4.7 mM KCl, 1.24 mM MgSO4, 3.3 mM CaCl2, 4% w/v BSA, 5 mM glu- 
cose, pH 7.4) for 2.5 h. 4% BSA is used to sequester FFAs and prevent their tendency to 
re-esterify with glycerol to form triglycerides. The remaining glycerol can thus be used as 
a measurement of lipolysis. Then, buffer was collected and analyzed for glycerol and 
fatty acid release under basal conditions. Glycerol and fatty acids were measured by 
using the serum triglyceride determination kit from Sigma-Aldrich and BioVision kit, 
respectively, according to the manufacturer’s instructions. 28 
Protein Quantification and Analysis 
Cells were lysed in cell lysis buffer (Cell Signaling) with 5% SDS, protease 
inhibitor cocktail (Roche Applied Science) and phosphatase inhibitor cocktail (Roche 
Applied Science). Protein lysates were then briefly sonicated, incubated in a 37 °C water 
bath for 30 min, and then centrifuged at 10,000 rpm for 10 min. The clear middle phase 
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of the solution was then collected as the protein sample. Protein quantification was 
performed using the Pierce BSA protein assay kit (Thermo Scientific)29.  
Western Blot  
Immunoblots (Western blot) were performed using 10 and 15% Tris-HCl gels 
(Bio- Rad), run at 100 volts for 90 min, and transferred to PVDF membranes (Bio-Rad), 
run at 60 volts, for 120 min. Primary antibodies used were all diluted in 2% BSA in TBS-
T. Antibodies used were: mouse anti- -tubulin (Invitrogen, 1:5000 dilution), rabbit anti-
FSP27 (1:4000 dilution), and rabbit IgG anti- ATGL (1:5000 dilution). Secondary 
antibodies were purchased from Santa Cruz Biotechnology (1:10000 dilution). 30 
Insulin Stimulation 
Insulin Stimulation of Human Adipocytes and Immunoblot Analysis of AKT 
Phosphorylation—Adipocytes plated in 12-well culture plates were washed three times in 
prewarmed PBS and then incubated at 37 °C for 2 hours in Krebs-Ringer HEPES buffer 
containing 0.01% BSA and 5 mM glucose for insulin and serum starvation. They were 
incubated for 15 min at 37 °C with Krebs-Ringer HEPES buffer with or without glucose 
but with 1 nM insulin. Cells were carefully washed three times with ice- cold PBS and 
harvested in 200 µl of lysis buffer containing phosphatase and protease inhibitor mixtures 
(Roche). Protein concentration was measured with a Bradford assay (Pierce BCATM 
protein assay). Equal amounts of protein were sepa- rated on 10% polyacrylamide gels 
and transferred to PVDF membranes. Nonspecific binding was blocked for 1 h at room 
temperature with 5% nonfat dry milk in Tris-buffered saline- Tween. Membranes were 
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incubated overnight at 4 °C with anti- body directed against total AKT (1:1000, Cell 
Signaling Technology) or phospho-AKT (Ser-473) (1:1000, Cell Signaling Technology). 
Anti-α-tubulin antibody was used as a loading control (1:10,000, Sigma-Aldrich). 
Appropriate horseradish peroxidase-conjugated secondary antibodies were used at 
1:10,00027.  
Real Time PCR  
Total RNA was isolated from human adipocytes from each well (12-well plate) 
with 1 ml of TRIzol (Invitrogen). Total RNA isolation was performed as described in the 
manufacturer's protocol, and RNA concentrations were measured on a NanoDropTM ND-
1000 spectrophotometer (Thermo Scientific). For quantitative PCR (mRNA analysis), 1 
µg of RNA was reverse-transcribed with Transcriptor first strand cDNA synthesis kit 
(Roche Applied Science). The cDNA was diluted 1:10, and 1 µl was used for each 
reaction (per well, 384-well plate) in triplicates. Primers (TaqMan) were used with Roche 
LightCycler 480 Probes Master kit (Roche Applied Science) at 0.25 µl, with 2.5 µl of 
master stock and 1.25 µl of ddH2O per reaction. Thermal cycling conditions were: 10 min 
at 95 °C for activation, 45 cycles of 10 s at 95 °C, 30 s at 60 °C, and 1 s at 72 °C for 
reactions, and 5 min at 37 °C for cooling down. The comparative ΔCt method was used 
to calculate relative changes in mRNA abundance in p53. The forward sequence for p53 
detection was 5’-AAAGTGCGTCCGTTCTCAATG-3’ and the reverse sequence was 5’- 
GGTTCTTCCTCAGAGTACCAAAG-3’ All standards were normalized using GAPDH.  
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Statistics  
Quantitative data are presented as mean ± S.D. Statistical significance 
was calculated using paired Student’s t test. A p value of ≤ 0.05 was 
considered statistically significant.	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RESULTS 
Selection of Natural Products 
Natural products that have studies in in vivo or in vitro rodent model systems, 
human model systems, and clinical trials were pursued as being viable experimental 
candidates (Figure 3A). Results were first filtered and categorized into natural products 
that pertain to obesity and diabetes and further filtered into natural products that are 
consistently represented in the research (Figure 3B). From these studies, natural products 
of interest based on their reputation in the literate, consistent evidence to support their 
claims and reliability of the experimental methodology. Four natural products were 
selected to begin initial tests on and assess their functionality across a range of tests: 
Bitter melon, fenugreek, ginseng, and almonds.  
A. B.  
Figure 3: Natural Product Selection Criteria A. Preferred studies as leads for natural 
products will be useful in all three rodent, rabbit, and human model systems. B. 
Truncated research list. See Appendix “Natural Products Research Tables” for entire 
chart 
Human	  (Whole	  Body	  &	  Tissue)	  
Mouse	  Rabbit	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The specific selection of the natural products was determined as a function of 
detailed and exhaustive inquires into their function and reported effects and the 
reproducibility of their findings in peer-reviewed settings. Almonds are naturally dense in 
phytosterols, soluble fiber, ω-6 fatty acids, and ω-9 fatty acids31. Almonds also have a 
low glycemic index and have been shown to help lower post-prandial blood glucose 
levels making the popular snack food a possible sensitizer of positive metabolic effects in 
patients with diabetes32. Fenugreek seeds have long been suggested to aid hypoglycemic 
and hypolipidemic properties in humans as well as having a potentiating effect in insulin 
secretion33,34. Ginseng has a storied history as a general panacea but certain species such 
as Panax ginseng have been implicated as reservoirs of active compounds known as 
ginsenosides which have been reported to decrease plasma glucose concentration in 
rodents, increase cellular glucose uptake, and perform as an anti-oxidant35–38. Bitter 
melon has been extensively studied with respect to the prevalence of components known 
as triterpenes which are reported to directly interact with the phosphorylation status of the 
insulin receptor and account for reductions in insulin resistance through interactions with 
PPAR-γ6,39–42. 
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Lipid Droplet Morphology 
A.  B.  
C.  D.  
E.  F.  
Figure 4: Adipocyte morphology under Natural Product Administration (A.) Almond. 
(B.) Bitter melon. (C.) Fenugreek. (D.) Ginseng. (E.) Cocktail of almond, bitter melon, 
fenugreek, and ginseng. (F.) Control. All cells represented were exposed to natural 
products concentrations of 20 μl/ml except for ginseng at a concentration 50 μl for 24 
hours in maintenance media 
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Larger lipid droplets were seen when contrasted against the fenugreek, almond, 
ginseng, or combination treatments (Figure 4). The observation of generally enlarged 
lipid droplets with each adipocyte encouraged further inquiry into the effects of our 
selected raw natural product extracts. Cells exposed to bitter melon consistently 
reproduced larger lipid droplet sizes relative to all other cell populations (Figure 4B). 
Compared to control cell populations, only bitter melon produced immediate visual 
differences (Figure 4F). The presence of larger lipid droplet sizes in the cocktail 
containing all four natural products suggests that bitter melon may have a role to play in 
the appearance of the increases in adipocyte lipid size (Figure 4E). 
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Lipolysis Analysis  
 Experiments with the four natural products were tested individually. The 
expression of lipolysis resulting from the application of specific natural products 
indicated that bitter melon raw extract application to human primary adipocytes resulted 
in the more interesting clinically relevant outcomes.  
 
Natural products affect adipocyte lipolysis in a dose dependent manner 
 
 
In order to test the efficacy of natural product administration, human 
subcutaneous adipocytes were exposed to concentrations of 5 µl/ml and 10 µl/ml and 

























Figure 5: Natural product administration to human adipocytes affects lipolysis in a dose 
dependent manner. All cells were incubated at 37℃ for 24 hours with concentrations of 0, 5 
µl/ml, or 10 µl/ml of ginseng, bitter melon, fenugreek, or almond extracts. Glycerol release 
was measured using a 2 hour exposure to 4% BSA and Krebs-Reactive Buffer  
  
	  	   22	  
their lipolysis rates were observed (Figure 5). The findings produced mixed results 
suggesting that with higher concentration almond extracts reduced lipolysis rates 
compared to control. Fenugreek showed no reduction in lipolysis rate. Bitter melon was 
shown to increase lipolysis rate at higher concentrations. Negative results are theorized to 
result from effects of cellular toxicity. The absolute threshold of toxicity is unknown for 
the administration of these individual natural products but studies from Neururkar et al on 
bitter melon have suggested that above 10% by volume reduced cell viability by 47%43.  
No statistical significance was observed in any cellular population. 
 
Natural products induce reduce lipolysis with increasing concentration 	  
	  


























Figure 6: Natural products reduce lipolysis with increasing concentration. All cells were 
incubated at 37℃ for 24 hours with concentrations of 0.1 µl/ml, 1 µl/ml, or 5 µl/ml of 
ginseng, bitter melon, or fenugreek, extracts and maintenance media. Glycerol release was 
measured using a 2 hour exposure to 4% BSA and Krebs-Reactive Buffer  
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 A subsequent look into the effect bitter melon may have on lipolysis suggests that 
when compared to the control rates of lipolysis, we observe see lower recorded rates of 
lipolysis in human subcutaneous adipocytes (Figure 6). Experimentally, toxicity appears 
to have resulted in the swings of observed lipolysis Natural products were administered 
in increasing concentrations of 0.1 µl/ml, 1 µl/ml and 5 µl/ml. Fenugreek, ginseng, and 
bitter melon extracts appeared to also suggest lower lipolysis rates than control 
populations. There were no statistically significant correlations between any natural 
product category or controls, however the changes do suggest a slight protective effect 
resulting from the administration of fenugreek and bitter melon natural products.  
Additionally, there appeared to be a reduction in lipolysis with increases in concentration. 
These results correlate strongly with existing literature that suggest bitter melon, 
fenugreek, and ginseng all have some anti-lipolytic effect in rodent model adipocytes 
37,44,45.  
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Bitter melon extracts increase lipolysis 
 
	  	   To	  establish	  whether	  or	  not	  bitter	  melon	  influenced	  any	  aspect	  of	  adipocyte	  morphology	  that	  may	  represent	  the	  observations	  of	  different	  adipocyte	  morphology,	  we	  tested	  the	  impact	  bitter	  melon	  had	  on	  human	  subcutaneous	  adipocyte	  rate	  of	  lipolysis.	  We	  observed	  that	  there	  was	  an	  apparent	  decrease	  in	  the	  lipolysis	  rate	  with	  the	  addition	  of	  5	  μl/ml	  of	  bitter	  melon	  extract.	  Although	  there	  was	  no	  statistical	  significance	  established	  between	  the	  control	  and	  these	  observations	  seem	  to	  align	  with	  findings	  from	  Nerurkar	  et	  al	  who	  demonstrated	  that	  increases	  in	  lipolysis	  may	  























Figure 7: Bitter melon extracts increase lipolysis. All cells were incubated at 37℃ for 24 
hours with concentrations of 0 or 5 µl/ml, or bitter melon almond extracts and maintenance 
media. Glycerol release was measured using a 2 hour exposure to 4% BSA and Krebs-
Reactive Buffer  
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be	  beneficial	  in	  reducing	  triglyceride	  accumulation	  and	  abating	  symptoms	  associated	  with	  obesity	  by	  limiting	  adipogenesis46.	  
 
Bitter melon extracts increase lipolysis in the presence of TNF-α  
	   It	  is	  known	  that	  in	  dyslipidemia,	  cytokines	  induce	  inflammation	  and	  affect	  adipocyte	  function47,48.	  The	  relationship	  between	  bitter	  melon	  and	  TNF-­‐α	  revealed	  that	  bitter	  melon	  increased	  the	  extent	  of	  lipolysis,	  especially	  in	  the	  presence	  of	  TNF-­‐α	  (Figure	  8).	  Changes	  in	  lipolysis	  were	  also	  tested	  across	  a	  range	  of	  concentrations	  of	  bitter	  melon.	  There	  were	  also	  statistically	  significant	  increases	  between	  the	  control	  group	  and	  the	  experiment	  groups	  with	  bitter	  melon	  without	  TNF-­‐α	  and	  with	  bitter	  melon	  including	  TNF-­‐α.	   
 



















Figure 8: Bitter melon extracts increase lipolysis in the presence of TNF-α. Cells 
with TNF-α were treated with 10ng/µl of TNF-α. Cells incubated at 37℃ for 24 
hours with of 0 µl/ml, 5 µl/ml, or 10 µl/ml of bitter melon extract & 10ng/ml of 
TNF-α. Glycerol measured using 2 hour exposure to 4% BSA & Krebs-Buffer  
	  	  	  Control	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Control	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We further investigated evidence suggesting a link between bitter melon extract 
and effects on adipocyte function. Western blot analysis was used to investigate the 
extent to which insulin signaling played a role in the administration of natural products to 
human subcutaneous adipocytes in the presence of TNF-α (Figure 9). The natural 
products almond, bitter melon, fenugreek, and ginseng, were introduced to subcutaneous 
Figure 9: Natural products resolve TNF-α induced insulin resistance. P-Akt 
exposed for 10 seconds. Total AKt exposed for 5 seconds. Ctrl: Control, B.M.: 
Bitter melon, Gsng: Ginseng, Fenu: Fenugreek, Almd: Almond. Lystates from 
adipocytes treated with 5 μl/ml of ginseng, fenugreek, bitter melon and 
almond were loaded at 40 μl per lane and probed with antibodies for Akt and 
phosphorylated Akt.  	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human adipocytes at a concentration of 5 µl/ml. Comparisons of phosphorylated-Akt to 
total Akt levels confirmed positive controls showing decreased insulin signaling in the 
presence of TNF-α and negative controls showed denser bands in the absence of insulin 
signaling suggesting no reduction in insulin signaling. Bitter melon showed more reduced 
level of insulin signaling that any other in the presence of TNF-a illustrating that there 
may be a minor ablation reduction in the signaling capacity of adipocytes due to the 
presence of TNF-a. Almond, fenugreek, and ginseng showed reduced insulin signaling 
however not to the clear level of reduction seen in bitter melon. The positive control for 
TNF-α did not result in the expected decrease that has been established in the literature 
however, and as such it is inconclusive as to how correlated the effects between the 
decrease of AKt signaling in bitter melon appears to be compared to fenugreek, ginseng, 
or almond extracts.  
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Fenugreek and Ginseng show p53 apoptotic signals in pre-adipocyte fibroblasts  
 
 
 Apoptosis has been recently investigated as a potential therapeutic for diabetes 
and obesity related conditions49. Administration of natural products to adipocytes may 
potentiate or express beneficial outcomes by inducing apoptosis of inflamed human 
subcutaneous adipocytes. Real-Time PCR (RT-PCR) was used to assess the presence of 
p53 protein as a marker of the induction of apoptosis in human pre-adipocytes treated 
with almond, bitter melon, fenugreek, and ginseng extracts in concentrations of 0, 1 
µl/ml, and 5 µl/ml. The up-regulation of p53 is very sharp and suggests massively 
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increased propensity towards the development of apoptosis at levels 55 to 65 times 
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DISCUSSION 
 Our goal was to assess the legitimacy of seemingly endless numbers of natural 
products and evaluate their reported effects to arrive at a handful of potentially beneficial 
compounds that may aid individuals with diabetes or obesity. Beginning with 
comprehensive investigations in literature, we compiled a body of natural products that 
were reported to be among the most researched and whose effects were consistently 
reported. After selecting our natural compounds, we used human primary adipocytes to 
study their effect on fat metabolism and insulin sensitivity. From the comprehensive 
literature survey we identified almond, bitter melon, fenugreek, and ginseng extracts as 
potential candidates for our further research. We demonstrated that the addition of 
almond, bitter melon, fenugreek, and ginseng extracts to cultured primary human 
adipocytes resulted in changes in adipocyte morphology, rate of lipolysis, insulin 
signaling, and signals of apoptosis. These findings are unique in the understanding that 
few studies have translated any findings of the impact of raw natural products from non-
human models to human adipocyte as a model system. The addition of natural products to 
human adipocytes has shown a reduction in the rate of lipolysis in bitter melon, 
fenugreek, and ginseng extracts. We initially observed that in concentrations higher than 
10 µl/ml we saw significant levels of toxicity in cellular lipolysis data. As a result, a 
secondary inquiry into the efficacy of natural products administration to adipocytes 
revealed not only decreases in rates of lipolysis for fenugreek, bitter melon, and ginseng, 
but also that the decrease in lipolysis was dose-dependent. In addition to observations of 
increased lipid droplet size of bitter melon relative to fenugreek, ginseng, or almond, we 
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also reported that when isolated, bitter melon extracts reduce the apparent lipolysis rate. 
Bitter melon extracts were also shown to increase lipolysis in the presence of TNF-α in 
increasing concentrations. We were able to point towards evidence suggesting that bitter 
melon reduced insulin signaling in cells treated with TNF-α implying that bitter melon 
may help to impair inflammatory mechanisms in adipocytes. Lastly we were able to test a 
novel concept suggesting that adipocyte apoptosis can be targeted as potential therapeutic 
for inflammation and obesity related ailments. We measured p53 mRNA sequences from 
pre-adipocytes treated with bitter melon, fenugreek, and ginseng and reported abnormally 
high expression levels at a rate of 50 to 60 times the amount of either the control or cells 
exposed to bitter melon. Future studies are planned to further elucidate the presence of 
other pro-apoptotic mRNAs such as BCL-2-associated death promoter and BCL-2 
homologous antagonist killer and an anti-apoptotic marker B-cell lymphoma 2 (BCL-
2)50. The comparison of lipolysis data, insulin signaling, and pro-apoptotic up-regulation 
allowed us to systematically address the influence that the raw natural products have on 
human adipocyte morphology and function. The narrowing throughout the effort to the 
effects of bitter melon resulted from an accumulation of information about bitter melon’s 
consistent and profound experimental performance. Taken together, bitter melon, and to a 
lesser extent ginseng and fenugreek, has the potential to serve as a supplement which 
reduces insulin resistance and acts to limit the effects of cytokine induced inflammation. 
 Obesity is associated with inflammation in adipose tissue as hypertrophy oocurs 
and also leads to increased lipolysis, thus increasing circulatory FFAs. In fact, increased 
FFAs in circulation leads to impaired insulin signaling in various tissues, thus leading to 
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insulin resistance and T2DM. In the case of our natural products, specifically bitter 
melon, lipolysis measurements demonstrate a protective effect against TNF-α induced 
lipolysis, and thus may act as a potential mediator of reducing symptoms associated with 
insulin resistance.  
Several aspects of our findings require follow-up and refinement. For example, 
we obtained inconsistencies in the protective effects of bitter melon, fenugreek, and 
ginseng in the presence of TNF-α in our western blot immunoassays in in contradiction 
with other studies which demonstrate such protective effects51–53. These observations 
render our results inconclusive despite evidence collected about the lipolytic effects of 
these selected natural products. Additionally, our analysis of p53 expression was wildly 
expressed and may indicate some component of experimental error. More experiments 
are required to further our research in the understanding that our natural compounds have 
adipocyte function in relation to T2DM and obesity. 
Since time immemorial, humans have sought to understand what unknown 
benefits may lie within the components of plants and endogenous substances from other 
animals. Whether or not any unknown natural compounds may have similar or superior 
effects to drugs or treatments has drive the development of modern medicine and shaped 
how individuals pursue remedies. The intimate connection between flora and fauna 
surrounding humanity in every environment is a storied history. The recent uptick in 
interest in natural product research has made investigations of the myriad of claims about 
the efficacy of natural products more accessible23,54. Many results obtained challenged 
conclusions reached in the literature, however it should be noted that within the realm of 
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natural products, the reported degree of efficacy often is challenged in many review 
articles such as Choi et al who suggest that the effects of ginseng administration to 
patience in clinical environments produced little to no observable effects55. However 
other wide spread reviews into bitter melon, for example, have suggested that not only 
are the apparent effects on adipocytes occurring, but mechanisms for their action have 
been elucidated by activating AMPK and inhibiting protein-tyrosine phosphatase 1B.56. 
Mechanisms for other natural products is limited and it remains to be seen what can be 
drawn from future studies that investigate the effects of natural product administration to 
human adipocytes. Moreover, the study of the raw application of natural products to 
adipocytes contrasts to most studies that take place and investigate isolated compounds 
from a specific natural product57. The benefit of isolating a single compound narrows the 
experimental focus of the natural compound’s efficacy but does not resemble the 
chemical diversity of the natural product when consumed under normal conditions.  
To most of the western world, there is skepticism and a community aimed 
towards challenging claims made by fans of traditional medical interventions. 
Furthermore, despite the information collected on the efficacy of these natural products 
and the experiment done on rodent model systems, translating the findings to clear human 
clinical outcomes is less transparent55,58,59. Information for many natural products is 
limited to small studies with mixed outcomes and information on human models systems 
remains limited in scope60. Longer term clinical studies are also required as many studies 
recruit either recruit not enough patients or their results have not been met with any 
significant degree of reproducibility in recent years61.  In the future, studies on natural 
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products will have to take place in institutions outside of environments where most of the 
mythology surrounding the efficacy of natural products pervades and heavily recruit 
across the academic spectrum to investigate the potential therapeutic influence of plant 
based natural products in diabetes and obesity.  	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